Buying Used CT and MRI: What Imaging Directors Must Verify Before Signing

Second-hand scanners can offer meaningful capital savings, but inadequate due diligence routinely turns those savings into liabilities.

Why this matters

Picture a 250-bed community hospital that acquires a refurbished 64-slice CT at roughly half the price of a comparable new unit. The installation goes smoothly, images pass an internal review, and clinical staff are satisfied — for about eight months. Then the X-ray tube fails. Replacement cost runs somewhere between $80,000 and $130,000 (OEM list prices in this category are not publicly published, but quotes in this range are widely reported by independent service organizations). The system sits idle for three weeks while procurement scrambles for a compatible tube, and the original capital savings are gone inside a single service event.

This is not an edge case. Used imaging capital — CT scanners, MRI systems, and their supporting infrastructure — is among the most technically complex used-equipment purchases a health system can make. Unlike a refurbished infusion pump, a secondhand CT or MRI carries long hardware lifecycles (the gantry frame or magnet bore may last 15 years), but much shorter lifecycles for the subsystems that determine clinical performance and uptime. The purchase price is often the smallest cost component over a ten-year horizon.

What makes the market genuinely useful right now is that refurbishment quality has improved substantially in many segments, and parts availability for major platforms remains strong for systems from roughly the last decade. However, "refurbished" is not a term regulated by the FDA. The agency draws a meaningful legal distinction between a remanufactured device — one altered sufficiently in intended use or performance to require a new 510(k) clearance — and a serviced device returned to original specifications. The secondary market frequently blurs that line, and the regulatory exposure associated with each category falls on the buyer's facility once the equipment is in clinical use.

The decisions that shape the outcome

Generation, vintage, and software lifecycle

The first substantive decision is how old a platform you're willing to accept. For CT, this largely tracks with slice count and acquisition architecture. Sixteen-slice systems remain clinically adequate for many routine applications but